Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 1.00 |
| ▸ | PARP1 | P09874 | 5/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797572 | 0.89 | PARP10 (0.81) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL24699354 | 0.86 | PARP10 (0.76) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL29676851 | 0.85 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL123731 | 0.85 | PARP10 (1.00) | PARP10PARP11PARP1PDPK1TDP2 | |
| SCHEMBL275805 | 0.81 | PARP10 (0.68) | PARP10PARP11PARP1TDP2GRM5 | |
| SCHEMBL1315035 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL15727824 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL13512608 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1TDP2F7 | |
| SCHEMBL2616889 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1TDP2 | |
| SCHEMBL794160 | 0.78 | PARP10 (0.74) | PARP10PARP11PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894363-B | Synthesis process of 6-bromo-1, 2,3, 4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-115894363-A | Synthesis process of 6-bromo-1,2,3,4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260101899-A1 | SULFONAMIDE COMPOUND AND HARMFUL-ARTHROPOD CONTROLLING COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-1045843-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5977134-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999028313-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| US-5780480-A | THROMBOLYTIC AGENTS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | PARP10 1988/4885PARP11 294/4885PARP1 462/4885 |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | PARP10 2546/4885PARP11 1703/4885PARP1 2221/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | PARP10 3928/4885PARP11 2087/4885PARP1 3091/4885 |
| US-20260101899-A1 | SULFONAMIDE COMPOUND AND HARMFUL-ARTHROPOD CONTROLLING COMPOSITION CONTAINING SAME | COX6B1, CYC1, COXFA4 | PARP10 4655/4885PARP11 4536/4885PARP1 4671/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | PARP10 3717/4885PARP11 2394/4885PARP1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.